curasan AG signs exclusive sales agreement with Zimmer Dental Inc., USA

curasan AG, listed in the General Standard of the German Stock Exchange, has signed an agreement which provides Zimmer Dental Inc, Carlsbad, CA, (USA) with exclusive global distribution rights. End Quote

(1888PressRelease) July 26, 2011 - Kleinostheim - curasan AG, listed in the General Standard of the German Stock Exchange (ISIN: DE 000 549 453 8), has signed an agreement which provides Zimmer Dental Inc, Carlsbad, CA, (USA) with exclusive global distribution rights for Osbone®, Ceracell® and Osseolive® synthetic bone grafting products for regenerative dental applications.

Zimmer Dental is expected to launch the granular forms of Osbone®, Ceracell®, and Osseolive® in late 2011 in countries where the products are commercially available. Putty and paste forms of these innovative, synthetic regenerative products are scheduled to follow.

"Zimmer Dental provides a well-established global sales structure in the dental market, and is experienced with biologicals and biomaterials," states Hans Dieter Rössler, CEO of curasan AG. "With Zimmer as a partner, we have the opportunity to achieve a leading position in the dental bone regeneration market, which is estimated to reach more than 250 million dollars annually within the next several years. This agreement is a significant development for curasan AG, and further confirms our strategy of investment in the development of leading edge products for regenerative medicine."

"Zimmer Dental continues to demonstrate a strong commitment to improving patients' lives through innovative products and technologies," said Harold C. Flynn, Jr., President, Zimmer Dental. "This agreement strengthens our industry-leading regenerative portfolio by allowing us to offer a variety of synthetic options to our diverse, global customer base."

Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading companies in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. Some of these various new developments are ready yet for market rollout. Further products are about to follow until the end of 2012. These biomaterials will be distributed in different submarkets by well-positioned contractual partners. www.curasan.com

Background information about Zimmer Dental Inc.:
Headquartered near San Diego in Carlsbad, California, Zimmer Dental has built a history of innovation and success with its trusted line of dental implants, prosthetics, and regenerative products. Proudly offering one of the most comprehensive dental implant product lines available, Zimmer Dental is a market leader in the development of world-class implantology products and educational programs focused on empowering clinicians and improving patients' lives. Zimmer Dental's parent company, Zimmer Holdings, Inc. (NYSE and SWX: ZMH), is a worldwide leader in joint replacement solutions for knee pain and hip pain, and provides comprehensive spine care solutions for acute and chronic back pain. The company also provides a broad range of trauma and orthopaedic surgical products. For more information, please visit Zimmer Dental at www.zimmerdental.com.

Press contact:
curasan AG
Andrea Weidner
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
andrea.weidner ( @ ) curasan dot de
www.curasan.de

fr financial relations gmbh
Jörn Gleisner
Tel. +49 (0)69 95 90 83 20

###

space

Other Related Press Releases